Xiao Lin
Direktor/Vorstandsmitglied bei Beijing Falikang Pharmaceutical Co. Ltd.
Ursprung des Netzwerks ersten Grades von Xiao Lin
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Xiao Lin
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
| FIBROGEN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Pharmaceuticals: Major | Chief Executive Officer | |
| FibroGen International (Cayman) Ltd. | Director/Board Member | ||
| FibroGen International (Hong Kong) Ltd. | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 4 |
| China | 2 |
| Cayman Islands | 2 |
| Hong Kong | 2 |
Sektoral
| Health Technology | 3 |
| Technology Services | 2 |
| Consumer Services | 2 |
Operativ
| Director/Board Member | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Christine Chung L. | 7 |
| Joseph Watson | 1 |
| Ai Min Fu | 1 |
| Lu Jin | 1 |
